Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the ...

A new analysis showed that hearing loss is associated with a greater risk for cognitive decline in middle-aged and older ...

If you’re having memory problems and are above 60, get tested for free to check if your cognitive health is really impaired.

Outcomes may improve with disease-modifying drugs and lifestyle change if Alzheimer's could be identified earlier.

Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Keegan to Lead Strategic Growth and Drive AI-Enabled Innovation in Digital Cognitive Health Solutions ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said it would cease development of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease due ...

When most people think of dementia, including Alzheimer's disease, they probably think of memory loss first. But dementia ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Further research could also help explain and even predict variation in the onset of behavioral changes in people with ...

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...